KRAS Mutation-Related Tumors clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

    open to eligible people ages 18 years and up

    This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant pancreatic ductal adenocarcinoma. These are subjects who have not previously been treated with anthracyclines.

    Orange, California

Our lead scientists for KRAS Mutation-Related Tumors research studies include .

Last updated: